ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator™ VAR 200 in a Patient with ApoCII Amyloidosis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 08 2025
0mins
Source: Newsfilter
ApoCII Amyloidosis and VAR 200: ApoCII amyloidosis is a rare condition affecting the kidneys, leading to proteinuria and chronic kidney disease. A patient receiving standard treatments continues to progress in kidney disease, prompting the use of VAR 200 under Emergency Compassionate Use, which aims to reduce lipid accumulation and improve kidney function.
ZyVersa Therapeutics' Role: ZyVersa Therapeutics supports the compassionate use of VAR 200 for the patient, highlighting its potential benefits based on preclinical studies. The company is advancing its clinical development pipeline for kidney diseases, including ongoing trials for diabetic kidney disease and plans for future indications.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
